The 29 portfolio companies we’ve helped build have attracted more than $2.3B of risk capital, employ close to 1,000 Canadians and have a combined value of $4B.
Kairos Therapeutics was a biopharmaceutical company that developed a proprietary next-generation antibody-drug conjugate platform. It was merged with Zymeworks in 2016